Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Orthopediatrics (KIDS) Research & Development (2016 - 2026)

Orthopediatrics has reported Research & Development over the past 11 years, most recently at $2.2 million for Q1 2026.

  • For Q1 2026, Research & Development fell 5.1% year-over-year to $2.2 million; the TTM value through Mar 2026 reached $9.0 million, down 13.53%, while the annual FY2025 figure was $9.1 million, 17.51% down from the prior year.
  • Research & Development for Q1 2026 was $2.2 million at Orthopediatrics, down from $2.3 million in the prior quarter.
  • Over five years, Research & Development peaked at $3.0 million in Q1 2024 and troughed at $1.7 million in Q2 2022.
  • A 5-year average of $2.5 million and a median of $2.4 million in 2023 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: soared 69.78% in 2023 and later dropped 22.53% in 2025.
  • Year by year, Research & Development stood at $2.5 million in 2022, then grew by 18.2% to $2.9 million in 2023, then decreased by 0.21% to $2.9 million in 2024, then dropped by 22.53% to $2.3 million in 2025, then fell by 1.24% to $2.2 million in 2026.
  • Business Quant data shows Research & Development for KIDS at $2.2 million in Q1 2026, $2.3 million in Q4 2025, and $2.3 million in Q3 2025.